Methods
This was a multicenter, open-label, single-sequence study. An oral drug
cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin was
administered to adult patients with MET- dysregulated advanced
solid tumors on Day 1, and then on Day 22 with capmatinib. Between Days
11 and 32, capmatinib 400 mg was administered twice daily to ensure the
attainment of steady state for drug-drug interaction (DDI) assessment.
Pharmacokinetics of cocktail drugs and safety of capmatinib were
evaluated.